10 results about "Epithelial tissue" patented technology

To provide a composition for promoting tight junction formation that promotes formation of tight junctions between epithelial tissue cells.SOLUTION: A composition for promoting tight junction formation for promoting formation of tight junctions between epithelial tissue cells, contains triterpenes and skim milk and / or wheat gluten, thereby solving the problem to be solved.SELECTED DRAWING: None

The invention relates to a dental prosthesis element (1) comprising a body (4) provided with a micro-structured surface (14), and a coating (15) covering the micro-structured surface, the coating being intended to come into contact with an epithelial tissue (12) and / or a connective tissue (13), the coating comprising zirconium nitride.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

The application relates to the technical field of cell culture, and particularly discloses a method for constructing an in-vitro layered culture model for observing the polarity of odontoblasts, which comprises the following steps: extracting mandibular incisor neck ring tissues, separating dental epithelial tissues and dental papilla tissues; separately digesting the dental epithelial tissues and the dental papilla tissues into single-cell suspensions; inoculating epithelial cells on the surface of movable polycaprolactone films for culture to obtain an epithelial cell-polycaprolactone film complex; carrying out adherent culture on dental papilla cells to proliferate, and pre-treating the dental papilla cells under experimental conditions during or after the culture; inoculating the pre-treated dental papilla cells in an upper chamber; adhering the epithelial cell-polycaprolactone film complex to a lower chamber; and removing the epithelial cell-polycaprolactone film complex. By adhering the epithelial cell-polycaprolactone film to the lower chamber for co-culture, the epithelial cells can induce the dental papilla cells to establish top-bottom polarity by relying on the gap of the chamber.

The invention relates to the technical field of cell culture, and particularly discloses an in-vitro layered culture model construction method for observing dentin cell polarity, and the method comprises the following steps: extracting mandibular incisor neck ring tissue, and separating odontogenic epithelial tissue from dental papilla tissue; respectively digesting the odontogenic epithelial tissue and the dental papilla tissue into single-cell suspensions; the method comprises the following steps: inoculating epithelial cells on the surface of a movable polycaprolactone membrane for culturing to obtain an epithelial cell-polycaprolactone membrane complex; performing adherent culture on the dental papilla cells for proliferation, and performing experimental condition pretreatment on the dental papilla cells in the culture process or after culture; inoculating the pretreated dental papilla cells into the upper chamber; the epithelial cell-polycaprolactone membrane complex is attached to a lower chamber; and the epithelial cell-polycaprolactone membrane complex is removed. Co-culture is realized by attaching an epithelial cell-polycaprolactone membrane to the lower part of the small chamber, and the epithelial cells can be utilized to induce dental papilla cells to establish top-bottom polarity by virtue of gaps of the small chamber.

The invention relates to an application of dihydroergomine in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. A brand-new action mechanism is obtained through verification in an inflammatory bowel disease model, wherein TRIM25 can mediate ubiquitination degradation of LSD1 under the inflammatory condition, metabolic disorder of intestinal epithelial tissue is caused, and inflammation is aggravated. According to the application disclosed by the invention, by predicting structural information of combination of the TRIM25 and the LSD1, virtual medicine is used for screening, a dihydroergomine small molecule compound is screened, and the dihydroergomine small molecule compound can well occupy a combination site of interaction of the TRIM25 and the LSD1 and inhibit the interaction of the TRIM25 and the LSD1, so that degradation of the LSD1 is inhibited; in a DSS-induced mouse colitis model, the dihydroergomine can relieve inflammation activation caused by metabolic disorder of intestinal epithelium and well relieve symptoms of the inflammatory bowel disease. In the process, the action mechanism is clear, the effect is remarkable, new application of the dihydroergomine in the aspect of treating the inflammatory bowel disease is realized, and the dihydroergomine has higher clinical application value.

The application provides a method for establishing a Bactrian camel intestinal tract organoid model and application thereof, and the method is as follows: mucous mucus of Bactrian camel intestinal tract tissue is scraped off, washed, digested, washed again, crypt cells are scraped, cells are suspended in a culture medium, screened, filtrate is collected, centrifuged, supernatant is discarded, cells are resuspended in a DMEM / F12 culture medium containing bovine serum albumin to obtain a cell suspension; matrix glue is added to the cell suspension, mixed uniformly, inoculated, grown, grown culture medium is added, and then the Bactrian camel intestinal tract organoid model is obtained; and the obtained Bactrian camel intestinal tract organoid model is subcultured. The application also provides application of the Bactrian camel intestinal tract organoid model constructed by the construction method, which is used for in-vitro model construction of Bactrian camel intestinal tract related drugs or / and biological products. The construction method can efficiently obtain the Bactrian camel intestinal tract organoid which has self-organization and self-renewal capabilities and highly simulates intestinal epithelial tissue, and realizes stable subculture.

The invention belongs to the technical field of primary cell culture, and particularly relates to a bronchial epithelial cell physiological or pathological model and a construction method and application thereof.The construction method comprises the steps that primary HBECs are provided, an amplification culture medium is used for conducting infiltration type amplification culture on the HBECs in a cell culture plug-in, after the cells form a complete barrier, the amplification culture medium is removed, and the model is obtained; carrying out gas-liquid interface culture on the cells in the cell culture plug-in by adopting a differential culture medium so as to induce the differentiation of the HBECs to form a false multi-layer columnar epithelial tissue structure; the cell culture plug-in comprises a porous membrane substrate, and construction of a physiological model or a pathological model is realized by selecting the cell culture plug-in of the porous membrane substrate with different pore diameters. According to the method, the in-vitro differentiation period of the HBECs can be remarkably shortened, and the model culture efficiency is greatly improved. The bronchial epithelium model capable of accelerating physiological differentiation or having pathological phenotype prepared by the method provided by the invention has significant advantages in drug screening and disease research.

The present invention relates to a method for producing a multi-tissue lung organoid structurally surrounded by fibroblasts, and a use thereof, and provides a three-dimensional structure composed of a lung organoid and a fibroblast layer surrounding the outside thereof. The organoid according to the present invention can maintain a high level of structural stability and bio-fidelity by reproducing a cell arrangement and microenvironment similar to those of actual lung tissue. The multi-tissue organoid more precisely reproduces a microenvironment in which epithelial tissues and interstitial tissues are arranged in layers as in a living body, rather than adopting a simple cell mixing method, and thus can be used in various biomedical applications, such as regenerative medicine, research on lung disease conditions, and evaluation of responsiveness to anticancer drugs and anti-fibrotic drugs. In addition, the present invention has excellent expandability to organoid-on-chip technology or bio-artificial organ development, and thus can be expected to be used as a precision medicine and next-generation cell therapy platform.